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The inflammation-dependent adhesion molecule expressions are characterized in
cardiovascular diseases and myocardial tissue infiltrations. Several pro-inflammatory
cytokines are elevated in the acute myocardial injury and infarction. Tumor necrosis
factor-α (TNF-α), a pro-inflammatory cytokine, is raised in the injury tissues and
inflammatory regions and involved in the pathogenesis of cardiac injury, inflammation,
and apoptosis. In fibroblasts, TNF-α-triggered expression of vascular cell adhesion
molecule (VCAM)-1 aggravated the heart inflammation. However, the mechanisms
underlying TNF-α-mediated VCAM-1 expression in cardiac fibroblasts remain unclear.
Here, the primary cultured human cardiac fibroblasts (HCFs) were used to investigate
the effects of TNF-α on VCAM-1 expression. The molecular evidence, including protein,
mRNA, and promoter analyses, indicated that TNF-α-induced VCAM-1 gene expression
is mediated through the TNFR-dependent manner. Activation of TNF-α/TNFR system
triggered PKCα-dependent NADPH oxidase (Nox)/reactive oxygen species (ROS) signal
linking to MAPK cascades, and then led to activation of the transcription factor, AP-
1. Moreover, the results of mRNA and promoter assay demonstrated that c-Jun/AP-1
phosphorylated by TNF-α turns on VCAM-1 gene expression. Subsequently, up-
regulated VCAM-1 on the cell surface of TNF-α-challenged HCFs increased the number
of monocytes adhering to these cells. These results indicated that in HCFs, activation of
AP-1 by PKCα-dependent Nox/ROS/MAPKs cascades is required for TNF-α-induced
VCAM-1 expression. To clarify the mechanisms of TNF-α-induced VCAM-1 expression
in HCFs may provide therapeutic strategies for heart injury and inflammatory diseases.
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INTRODUCTION
Cardiovascular diseases are characterized by overexpression of
inﬂammatory genes and inﬁltration of the inﬂammatory cells
via adhesion molecule induction such as VCAM-1 (Bedard
and Krause, 2007; Cheng et al., 2009; Cook-Mills et al., 2011).
Previous report indicates that the elevated levels of adhesion
molecules (e.g., VCAM-1) have been detected in the serum
of non-ischemic heart failure patients and the inﬂammatory
inﬁltrations in the myocardial tissue (Cronstein, 1994). In
polymorphonuclear cells (PMNs), induction of adhesion
molecules can mediate the tight cellular adhesiveness and thus
facilitate PMNs migration across the vascular endothelial barrier
(Dustin et al., 1988; Frangogiannis et al., 2002). The cardiac
ﬁbroblasts exhibit versatile ability through the potential to
activate a series of genes that initiate and amplify inﬂammation
in heart diseases. Additionally, up-regulation of VCAM-1
and tumor necrosis factor-α (TNF-α) can be detected in the
cardiac vascular endothelium of chronic heart failure patients
(Cronstein, 1994; Savic-Radojevic et al., 2013). Therefore,
up-regulation of VCAM-1 expression on cytokine-triggered
heart diseases may be the key factor responsible for the
targeted leukocyte transmigration into extra-vascular space of
inﬂammation (Dustin et al., 1988; Frangogiannis et al., 2002).
Heart diseases are associated with acute myocardial injury
initiating a sequence of events that often lead to cardiac
hypertrophy, chamber dilation, interstitial ﬁbrosis, and
congestive heart failure (Communal and Braunwald, 2005).
Several pro-inﬂammatory cytokines are elevated in patients and
animal models of acute myocardial injury and infarction, which
may cause phenotypic and functional changes in the constituent
cell types of the heart (Javaid et al., 2003; Hsieh et al., 2012;
Kim et al., 2012), including generation of various mediators
by cardiac ﬁbroblast (Klein et al., 1998; Kono et al., 2003; Kim
et al., 2013). Therefore, chronically raised pro-inﬂammatory
cytokines, including TNF-α, IL-6, IL-1, and IL-18, could aﬀect
the cardiac structure and function during heart injury and
infarctions. Such as TNF-α and IL-6, these pro-inﬂammatory
cytokines play key roles in the pathological process dependent
on their concentrations in primary insults (Koudssi et al., 1998;
Hedayat et al., 2010). Among these, TNF-α may be a prominent
cytokine in the pathogenesis of cardiac injury, inﬂammation,
and apoptosis (LeBel et al., 1992; Kyriakis and Avruch, 2001).
TNF-α triggers up-regulation of many genes (including adhesion
molecules) to initiate inﬂammatory responses (Lee et al., 2006).
Recent study also showed that inhibition of TNF-α-mediated
pathways reduces myocardial ischemia-reperfusion injury
(Kyriakis and Avruch, 2001). These results suggest that TNF-α
exerts potential mediators in heart inﬂammatory diseases.
Reactive oxygen species (ROS) are generated by several
enzymatic reactions and chemical processes or directly inhaled,
including O·−2 , OH·, and hydrogen peroxide (H2O2). Low
levels of these oxidative-contained molecules are required for
maintaining normal physiological functions and protecting
against invading microorganisms (Lee et al., 2008). Among
these, various approaches indicate that NADPH oxidase (Nox)
complex is considered to be a major source of ROS generation
(Rahman et al., 2006; Lin et al., 2012; Lee and Yang, 2013).
It has been shown that overproduction of ROS acts as a risk
factor leading to impairing cellular functions and enhancing
inﬂammatory responses (Kolluru et al., 2012; Lee and Yang,
2012). In the cardiovascular system, low levels of ROS contribute
tomaintenance of cellular redox homeostasis. Under pathological
states, excessive ROS production by several pro-inﬂammatory
mediators like cytokines can induce expression of various
inﬂammatory genes during heart disorders (Bhagat and Vallance,
1997; Libby, 2002; Lin et al., 2015). Accumulating evidences
have indicated that ROS generation acts as a deleterious signal
that leads to damage of heart cells and heart inﬂammatory
injuries/diseases. ROS are also known to be implicated in the
pathogenesis and deterioration of various cardiac disorders, such
as myocardial infarction (MI) and heart failure (Looi et al., 2008;
Hori and Nishida, 2009; Lin et al., 2015). Therefore, increasing
evidence has shown that Nox-derived ROS production may
contribute to regulation of several inﬂammatory mediators in
heart diseases (Lambeth, 2007; Yang et al., 2013a). However,
the pathways of VCAM-1 expression via TNF-α-initiated ROS
generation remain to be deﬁned in human cardiac ﬁbroblasts
(HCFs).
TNF-α induces expression of several inﬂammatory genes by
activation of TNF receptor (TNFR)-mediated diverse signaling
molecules, including PKCs, ROS, MAPKs, and transcription
factors (Palmer et al., 1995; Lin et al., 2012). Previous
studies suggest that the MAPK pathway is involved in several
pathophysiological processes of heart diseases (Rajesh et al., 2003;
Palomer et al., 2013). In addition, p42/p44 MAPK, p38 MAPK,
and JNK1/2, the three well characterized MAPK subfamilies,
are the targets of pharmacological and genetic manipulations
to explore their roles in cardiac development, function, and
diseases (Ravingerova et al., 2003). Moreover, activation of
MAPKs leading to expression of inﬂammatory genes by ROS
has been shown in various cell types (Reinehr et al., 2007).
The previous studies have also shown that MAPK activation
is involved in the up-regulation of VCAM-1 in various cell
types (Reinehr et al., 2007; Rose et al., 2010; Lee et al., 2012).
Recent study demonstrated the involvement of Nox-dependent
ROS generation in TNF-α-induced MMP-9 expression in rat
heart-derived H9c2 cells (Kim et al., 2012; Yang et al., 2013a).
The transcription factor activator protein 1 (AP-1) is critical
for inﬂammatory processes induced by various stimuli including
cytokines (Lee et al., 2006; Saito et al., 2012). Moreover, the
expression of VCAM-1 and other genes appears to be up-
regulated by ROS and AP-1 in various cell types (Siwik et al.,
2000; Reinehr et al., 2007; Savic-Radojevic et al., 2013). VCAM-1
promoter also contains AP-1 binding sites which are regulated
by TNF-α through MAPKs-mediated pathways in several cell
types (Szekanecz et al., 1996; Siwik et al., 2000). Therefore, we
examined whether these signaling components are involved in
the TNF-α-induced VCAM-1 expression in HCFs.
In the study, to investigate the molecular mechanisms
of TNF-α-mediated responses in HCFs, we found that
Nox/ROS-mediated pathways were involved in VCAM-1
induction. These results demonstrated that TNF-α induces
TNFR1/PKCα-dependent Nox/ROS/MAPKs cascade in HCFs.
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Through this pathway, TNF-α promoted the activation of
c-Jun/AP-1 to increase VCAM-1 transcription and resulting
in the VCAM-1 protein expression in HCFs. Moreover, we
found that the increased VCAM-1 expression contributes with
monocytes adhesion to TNF-α-challenged HCFs.
MATERIALS AND METHODS
Materials
DMEM/F-12 medium, fetal bovine serum (FBS), TRIzol reagent
and PLUS-Lipofectamine were from Invitrogen (Carsbad, CA,
USA). Hybond C membrane and enhanced chemiluminescence
(ECL) detection system were from GE Healthcare Biosciences
(Buckinghamshire, UK). PhosphoPlus PKCα (#9375), p42/p44
MAPK (#9101), p38 MAPK (#9211), JNK1/2 (#4668), and c-Jun
(#2361) antibody kits were from Cell Signaling (Danver, MA,
USA). VCAM-1 (sc-8304), PKCα (sc-208), Nox2 (sc-20782),
Nox4 (sc-30141), p42 (sc-154), p38α (sc-535), JNK1 (sc-474), and
c-Jun (sc-1694) antibody were from Santa Cruz (Santa Cruz, CA,
USA). Ro31-8220, Gö6976, Edaravone, dipheneyleneiodonium
chloride (DPI), U0126, SB202190, SP600125, and tanshinone
IIA (TSIIA) were from Biomol (Plymouth Meeting, PA, USA).
Apocynin (APO) was from Cayman (Ann Arbor, MI, USA).
GAPDH antibody was from Biogenesis (Bournemouth, UK).
Bicinchoninic acid (BCA) protein assay kit was from Pierce
(Rockford, IL, USA). SDS-PAGE reagents were from MDBio Inc
(Taipei, Taiwan). Enzymes and other chemicals were from Sigma
(St. Louis, MO, USA).
HCFs Culture and Treatment
Human cardiac ﬁbroblasts isolated from human fetal heart were
obtained from ScienCell Research Laboratories (Carlsbad, CA,
USA) and grown in DMEM/F-12 containing 10% FBS, 2 mM
glutamine and antibiotics (100 U/ml penicillin G, 100 μg/ml
streptomycin, and 250 ng/ml fungizone) at 37◦C. Reaching
conﬂuence, cells were treated with 0.05% trypsin/0.53 mM
EDTA and plated onto 12-well culture plates and made
quiescent at conﬂuence by incubation in serum-free DMEM/F-
12 for 24 h, and then incubated with TNF-α at 37◦C
for the indicated time intervals. When the inhibitors were
used, cells were pretreated with the inhibitors for 1 h
before exposure to TNF-α. Treatment of HCFs with DMSO,
pharmacological inhibitors, or TNF-α alone had no signiﬁcant
eﬀect on cell viability determined by an XTT assay (data not
shown). Experiments were performed using cells from passages
3 to 6.
Preparation of Cell Extracts and Western
Blot Analysis
After treatment with TNF-α, HCFs were washed with ice-
cold PBS, scraped, and collected by centrifugation at 45,000×g
for 1 h at 4◦C to yield the whole cell extract, as previously
described (TorreAmione et al., 1996). Samples were denatured
and separated by 10% SDS-PAGE. The transferred nitrocellulose
membranes were blocked with 1% BSA in TTBS (50 mM Tris-
HCl, pH 7.4; 150 mM NaCl; 0.1% Tween 20) for 30 min
and then probed with a respective primary antibody (1:1000)
overnight at 4◦C. The washed membranes were incubated
with an anti-rabbit horseradish peroxidase antibody (1:2000)
for 1 h. The immunoreactive results were detected with ECL
reagents and captured by a UVP BioSpectrum 500 Imaging
System (Upland, CA, USA). UN-SCAN-IT gel software (Orem,
UT, USA) was used to analyze and quantify the image
densitometry.
Total RNA Extraction, Real time-PCR,
and PCR Analysis
Human cardiac ﬁbroblasts were seeded on 10-cm culture
dishes and treated with TNF-α. Total RNA were extracted
with TRIzol reagent (Thermo Fisher, Waltham, MA, USA)
according to the protocol of the manufacturer. The cDNA
obtained from 0.5 μg total RNA was used to be a template
for PCR ampliﬁcation (TorreAmione et al., 1996). Real-time
PCR was performed with KAPA PROBE FAST ABI Prism R©
qPCR kit (KK4705, Kapa Biosystems, Wilmington, MA, USA)
and 7500 Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA) using VCAM-1 primers and probe mixture
(Forward: WSO_645213_001; Reverse: WSO_645213_002;
Probe: WSO_645213_003; Invitrogen, Carlsbad, CA, USA)
and endogenous GAPDH (Forward: WSO_724786_001;
Reverse: WSO_724786_002; Probe: WSO_724786_003;
Invitrogen) served as an internal control gene. Relative
gene expression was determined by the Ct method, where
Ct meant threshold cycle. All experiments were performed in
triplicate. PCR were performed to analysis the expressions of
NOX1 (Forward: 5′-CTTCCTCACCGGATGGGACA-3′;
Reverse: 5′-TGACAGCATTTGCGCAGGCT-3′; replicon:
218 bp), NOX2 (Forward: 5′-TGTCCAAGCTGGAGTGGCAC-
3′; Reverse: 5′-GCACAGCCAGTAGAAGTAGAT-3′; replicon:
321 bp), NOX3 (Forward: 5′-GAGTGGCACCCCTTCACCCT-
3′; Reverse: 5′-CTAGAAGCTCTCCTTGTTGT-3′; replicon:
708 bp), Nox4 (Forward: 5′-AGTCAAACAGATGGGATA-3′;
Reverse: 5′-TGTCCCATATGAGTTGTT-3′; replicon: 240 bp),
Nox5 (Forward: 5′-ATGAGTGGCACCCCTTCACCATCAG-
3′; Reverse: 5′-GTCAGCAGGCTCACAAACCACTCGAA-3′;
replicon: 501 bp) and β-actin (Forward:5′-TGACGGGG
TCACCCACACTGTGCCCATCTA-3′; Reverse: 5′-CATGAA
GCATTTGCGGTGGACGATG-3′; replicon: 636 bp) was used to
be the internal control.
Plasmid Construction, Transfection, and
Luciferase Reporter Gene Assays
To construct VCAM-1-Luc plasmids, human VCAM-1 promoter
region from -1716 to -119 bp (kindly provided by Dr.
W.C. Aird, Department of Molecular Medicine, Beth Israel
Deaconess Medical Center, Boston, MA, USA), was inserted
into pGL3-basic vector (Promega, Madison, WI). The AP-
1 and VCAM-1-Luc transcription activities were determined
as previously described (TorreAmione et al., 1996) using a
luciferase assay system (Promega, Madison, WI) to analyze the
ﬁreﬂy luciferase activities and standardize with β-galactosidase
activity.
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Transient Transfection with siRNAs
HCFs (80% conﬂuence) were washed once with PBS and
0.4 ml of serum-free DMEM/F-12 medium was added to
each well. Human siRNAs of scrambled, PKCα (L-003523-
00-0020) was from Dharmacon (Lafayette, CO) and Nox2
(SASI_Hs01_00086110), Nox4 (SASI_Hs02_00349918), p42
(SASI_Hs01_00058601), p38α (SASI_Hs01_00176564), JNK1
(SASI_Hs02_00319556), and c-Jun (SASI_Hs02_00333461) were
from Sigma (St. Louis, MO). Transient transfection of siRNAs
(100 nM) was performed using a LipofectamineTM RNAiMAX
reagent according to the manufacturer’s instructions (Invitrogen,
Carsbad, CA, USA).
Measurement of Intracellular ROS
Generation
The peroxide-sensitive ﬂuorescent probe 2′,7′-
dichloroﬂuorescein diacetate (DCF-DA) was used to assess the
generation of intracellular ROS (Vesely et al., 2009) with minor
modiﬁcations. HCFs were incubated with 5 μM DCF-DA in
serum-free DMEM/F-12 at 37◦C for 45min. The supernatant was
removed and replaced with fresh DMEM/F-12 medium before
exposure to TNF-α (15 ng/ml). Relative ﬂuorescence intensity
was recorded at the indicated time by using a ﬂuorescent plate
reader (Thermo, Appliskan) at an excitation wavelength of
485 nm and emission was measured at a wavelength of 530 nm.
Determination of NADPH Oxidase
Activity by Chemiluminescence Assay
The Nox activity was examined by lucigenin chemiluminescence
assay according to the previous report (Hsieh et al., 2012) with
minor modiﬁcation. The treated cells were gently scraped and
centrifuged at 400×g for 10 min at 4◦C. The cell pellet was
resuspended in 35 μl of ice-cold PBS and kept on ice. To a
ﬁnal 200 μl of PBS (pre-warmed at 37◦C) containing either
NADPH (1 μM) or NADH (1 μM) and lucigenin (20 μM),
5 μl of cell suspension (2 × 104 cells) was added to initiate
the reaction followed by measurement of chemiluminescence
immediately using an out-of-coincidence mode of Appliskan
luminometer (ThermoR©). Appropriate blanks and controls were
established, and recorded chemiluminescence. Neither NADPH
nor NADH enhanced the background chemiluminescence of
lucigenin alone (30–40 counts/min). Chemiluminescence was
continuously detected for 12 min, and the activity of Nox was
expressed as counts per million cells.
Cell Adhesion Assay
The human monocytic cell line THP-1 cells were obtained from
ATCC (Manassas, VA, USA) and maintained in DMEM/F-12
medium containing 10% FBS at 37oC. Cell adhesion assay was
modiﬁed from the previous report (Liu et al., 2013). In Brief,
HCFs were placed on 6-well culture plates with cover slips. The
cells were pretreated with the pharmacological inhibitors for
1 h and then treated with TNF-α for another 16 h at 37oC.
THP-1 cells were maintained and suspended in DMEM/F-12
containing 10% FBS. THP-1 cells were washed, resuspended
in serum-free DMEM/F-12, and incubated with BCECF/AM
(10 μM, Invitrogen) for 1 h at 37◦C to label the THP-1 cells.
The BCECF-labeled cells were washed thrice with serum-free
DMEM/F-12, resuspended in serum-free DMEM/F-12, kept in
the dark at room temperature and then the labeled THP-1 cells
were added to HCFs for 1 h. Gently washing the plate with
serum-free DMEM/F-12 to remove the non-adherent cells, the
number of adherent cells was observed by using a ﬂuorescence
microscope (ZEISS, Axiovert 200M).
Statistical Analysis of Data
All the data were expressed as the mean or mean ± SEM of ﬁve
individual experiments performed in duplicate or triplicate. All
these quantiﬁed numbers (mean ± SEM) related to the group
data were presented and described in Supplementary Tables S1
and S2. The signiﬁcance of diﬀerence between two groups was
determined by paired two-tailed Student’s t-test for western blot
data. All others statistical analyses are comparison of multiple
groups, a GraphPad Prism Program (GraphPad, San Diego, CA,
USA) by one-way analysis of variance (ANOVA) followed with
Tukey’s post hoc test has been used. A P < 0.05 value was
considered signiﬁcant.
RESULTS
TNF-α Induces VCAM-1 Expression via
PKCα
PKCα has been shown to regulate the expression of several
proteins in various cell types (Yang et al., 2005; Lee et al.,
2006; Whaley-Connell and Sowers, 2012). To determine the
eﬀects of PKCs on VCAM-1 expression, pretreatment of
HCFs with either pan-PKC inhibitor Ro31-8220 or a selective
PKCα inhibitor Gö6976 concentration-dependently attenuated
TNF-α-induced VCAM-1 protein expression (Figure 1A).
TNF-α-induced VCAM-1 mRNA expression and promoter
activity was also inhibited by Gö6976 (1 μM) (Figure 1B).
Next, the involvement of PKCα in TNF-α-induced responses
was conﬁrmed by determining its phosphorylation. TNF-α time-
dependently stimulated PKCα phosphorylation with a maximal
response within 15–30 min, which was attenuated by transfection
with PKCα siRNA (Figure 1C, from 2.5-fold to 1.4-fold).
Moreover, to ensure PKCα activity was involved in VCAM-1
expression, VCAM-1 protein was also analyzed in the PKCα
siRNA transfected HCFs. We found that PKCα knockdown
attenuated TNF-α-induced VCAM-1 expression about 65%
(Figure 1D, from 2-fold to 1.3-fold). Our data suggested that
the activity of PKCα transmits the TNF-α stimulation to induce
VCAM-1 expression via enhancing its gene transcriptional
activity in HCFs.
ROS Involved in TNF-α-Induced VCAM-1
Expression
Previous report indicates that ROS can induce expression
of adhesion molecules in various cell types (Savic-Radojevic
et al., 2013). To determine whether ROS contribute to VCAM-
1 induction by TNF-α in HCFs, pretreatment of Edaravone
Frontiers in Pharmacology | www.frontiersin.org 4 January 2016 | Volume 6 | Article 310
Lin et al. TNF-α-Induced VCAM-1 Expression in Cardiac Fibroblasts
FIGURE 1 | TNF-α induces VCAM-1 expression via PKC(α)-dependent pathway in HCFs. (A) HCFs were pretreated with Ro31-8220 (0.01, 0.1, or 1 μM) or
Gö6976 (0.1, 0.3, or 1 μM) for 1 h, and then incubated with TNF-α (15 ng/ml) for 16 h. The protein levels of VCAM-1 were analyzed by Western blot. (B) HCFs were
pretreated with Gö6976 (1 μM) for 1 h, and then incubated with TNF-α for 4 h. The mRNA expression of VCAM-1 was determined by real-time PCR (white bar). The
VCAM-1 promoter activity was detected by promoter-luciferase report assay (gray bar). (C,D) Cells were transfected with either scrambled or PKCα siRNA, and then
incubated with TNF-α for the interval time as indicated (C) or for 16 h (D). Western blots were performed to analyze the levels of phospho-PKCα (C), and total PKCα
or VCAM-1 protein (D). Data are expressed as mean ± SEM of three independent experiments (n = 3, Quantitative data of Figures 1C,D were presented in
Supplementary Table S1). ∗P < 0.05; #P < 0.01, as compared with the cells exposed to TNF-α alone.
(Eda, ROS scavenger, 10 μM) was followed with TNF-α
treatment. We found that Edaravone also attenuated the TNF-
α-induced VCAM-1 protein expression in a concentration-
dependent manner (Figure 2A). Besides, both of VCAM-1
mRNA expression and promoter activity induced by TNF-α were
attenuated by Edaravone (10 μM) (Figure 2B). To evaluate
the eﬀect of TNF-α-stimulated ROS generation, as shown in
Figure 2C, we found that TNF-α treatment time-dependently
stimulated ROS generation and the maximal ROS generation was
obtained within 60 min. This TNF-α-stimulated ROS generation
was attenuated by pretreatment with Edaravone. These results
demonstrated that Edaravone can eﬃciently scavenge ROS to
block the VCAM-1 expression, suggesting that ROS generation




Nox complex is considered to be a major source of cytoplasmic
ROS generation implicated in physiological and pathological
processes (Yokoyama et al., 1997; Yang et al., 2013b). To
investigate whether TNF-α activated Nox to generate ROS
leading to VCAM-1 expression, Nox inhibitor DPI was used to
block the TNF-α-activated Nox activity. As shown in Figure 3A,
we pointed out that pretreatment with DPI attenuated TNF-
α-induced VCAM-1 protein expression. Moreover, both VCAM-
1 mRNA expression and promoter activity induced by TNF-
α were also inhibited by 1 μM DPI (Figure 3B). To further
investigate whether TNF-α stimulates Nox activity, we found
that TNF-α time-dependently stimulated Nox activity with a
maximal response within 60 min in HCFs (Figure 3C). We
also determined which Nox isoforms are expressed and involved
in the TNF-α-mediated responses. RT-PCR was performed to
analyze the expression of Nox isoforms in HCFs. We found
that Nox1, Nox2, Nox4, and Nox5 mRNA, in particular Nox4,
can be detected in HCFs (Figure 3D). Next, transfection with
siRNAs of Nox isoforms was performed to conﬁrm the roles
of Nox(s) involved in the TNF-α-induced responses. As shown
in Figure 3E, transfection with either Nox2 or Nox4 siRNA
exhibited the consistent results that knockdown of the respective
Nox protein expression can attenuate TNF-α-induced VCAM-
1 expression in HCFs. Moreover, pretreatment with DPI (an
inhibitor of Nox) abolished TNF-α-stimulated Nox activity
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FIGURE 2 | Reactive oxygen species (ROS) signal is involved in
TNF-α-induced VCAM-1 expression in HCFs. (A) HCFs were pretreated
with edaravone (0.1, 1, or 10 μM) for 1 h, and then incubated with TNF-α for
16 h. The protein levels of VCAM-1 were determined by Western blot.
(B) HCFs were pretreated with edaravone (10 μM) for 1 h, and then incubated
with TNF-α for 4 h. The mRNA expression (white bar) and promoter activity
(gray bar) of VCAM-1 were determined by RT/real-time PCR or promoter
report assay, respectively. (C) HCFs were incubated with the DCF-DA (5 μM)
for 45 min, followed by pretreatment with (or without) edaravone (10 μM) and
stimulation with TNF-α for the indicated time intervals or 60 min in the
presence of edaravone. The fluorescence intensity of cells was determined.
Data are expressed as mean ± SEM of three independent experiments
(n = 3). ∗P < 0.05; #P < 0.01, as compared with the cells exposed to TNF-α
alone for 60 min.
and ROS generation (Figure 3F). To further investigate the
role of TNFR-mediated PKC(α) pathway in TNF-α-stimulated
Nox activity and ROS generation, pretreatment with TNFR
neutralizing antibody (TNFR nAb) or Gö6976 blocked TNF-
α-stimulated Nox activity and ROS generation (Figure 3F).
These results suggested that TNF-α stimulates Nox(2/4)-derived
ROS generation via TNFR-dependent PKCα cascade leading to
VCAM-1 expression in HCFs.
Involvement of p42/p44 MAPK in
TNF-α-Induced VCAM-1 Expression
Activation of MAPKs plays a key role in the pathogenesis
of heart diseases such as myocardial hypertrophy (Rajesh
et al., 2003; Palomer et al., 2013). To determine the role
of p42/p44 MAPK in VCAM-1 expression, pretreatment
with a MEK1/2 inhibitor U0126 concentration-dependently
attenuated TNF-α-induced VCAM-1 expression (Figure 4A).
U0126 (100 nM) also repressed TNF-α-induced VCAM-1
mRNA expression and transcription activity (Figure 4B).
To investigate whether TNF-α-induced responses are
mediated through activation of p42/p44 MAPK. The
results of Figure 4C indicated that TNF-α treatment time-
dependently stimulated p42/p44 MAPK phosphorylation
with a maximal response within 10–15 min, which was
attenuated by U0126 (100 nM). To further ensure the role
of p42/p44 MAPK in regulation of VCAM-1-expression, p42
MAPK siRNA transfection was used to knock down p42
protein. We found that knockdown of p42 protein by p42
siRNA transfection also attenuated TNF-α-induced VCAM-
1 expression (Figure 4D). In addition, pretreatment with
not only U0126, but also TNFR nAb (10 μg/ml), Gö6976
(10 μM), Edaravone (10 μM), and DPI (10 μM), could
attenuate TNF-α-stimulated p42/p44 MAPK phosphorylation
(Figure 4E). These results suggested that TNF-α triggers
the p42/p44 MAPK phosphorylation leading to VCAM-1
induction via a TNFR-mediated PKCα/Nox/ROS pathway in
HCFs.
Involvement of p38 MAPK in
TNF-α-Induced VCAM-1 Expression
To investigate the eﬀect of p38 MAPK on VCAM-1
induction, pretreatment with a p38 MAPK inhibitor SB202190
concentration-dependently attenuated TNF-α-induced VCAM-
1 expression (Figure 5A). Pretreatment with SB202190
(10 μM) also attenuated TNF-α-induced VCAM-1 mRNA
expression and transcription activity (Figure 5B). To determine
whether the activation of p38 MAPK was required for
TNF-α-mediated responses, as shown in Figure 5C, TNF-
α time-dependently stimulated phosphorylation of p38
MAPK with a maximal response within 10 min, which was
prevented by SB202190 (10 μM). To further conﬁrm the
role of p38 MAPK in TNF-α-induced VCAM-1 expression,
transfection with p38 MAPK siRNA to knock down p38
protein. We observed that knockdown of p38 protein also
attenuated TNF-α-induced VCAM-1 expression (Figure 5D).
Moreover, phosphorylation of p38 MAPK stimulated by
TNF-α was also attenuated by pretreatment with TNFR nAb
(10 μg/ml), Gö6976 (10 μM), Edaravone (10 μM), or DPI
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FIGURE 3 | NADPH oxidase-dependent ROS generation contributes to TNF-α-induced VCAM-1 expression in HCFs. (A) HCFs were pretreated without or
with DPI (0.01, 0.1, or 1 μM) for 1 h before exposure to TNF-α for 16 h. The protein levels of VCAM-1 were determined by Western blot. (B) HCFs were pretreated
with DPI (1 μM) for 1 h, and then incubated with TNF-α for 4 h. The mRNA expression (white bar) and promoter activity (gray bar) of VCAM-1 were determined by
RT/real-time PCR or promoter report assay, respectively. (C) HCFs were incubated with TNF-α for the indicated time intervals. The Nox activity was analyzed.
(D) The mRNA expression of Nox isoforms were determined by RT-PCR analysis. (E) Cells were transfected with either scrambled or siRNA for Nox2 and Nox4, and
then incubated with TNF-α for 16 h. The levels of Nox2, Nox4, and VCAM-1 protein were determined by Western blot. (F) HCFs were pretreated without or with DPI
(1 μM), TNFR nAb (10 μg/ml), or Gö6976 (1 μM) for 1 h and then incubated with TNF-α for 60 min. The Nox activity (gray bar) and ROS generation (white bar) were
analyzed as described in Section “Materials and Methods”. Data are expressed as mean ± SEM of three independent experiments (n = 3, Quantitative data of
Figures 3E,F were presented in Supplementary Table S1). ∗P < 0.05; #P < 0.01, as compared with the cells exposed to vehicle (C) or TNF-α (A,B,F) alone.
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FIGURE 4 | TNF-α-induced VCAM-1 expression is mediated through p44/p42 MAPK in HCFs. (A) HCFs were pretreated with U0126 (1, 10, or 100 nM) for
1 h, and then incubated with TNF-α for 16 h. The protein levels of VCAM-1 were determined by Western blot. (B) HCFs were pretreated with U0126 (100 nM) for
1 h, and then incubated with TNF-α for 4 h. The mRNA expression (white bar) and promoter activity (gray bar) of VCAM-1 were determined by real-time PCR or
promoter report assay, respectively. (C) HCFs were pretreated with U0126 (100 nM) for 1 h, and then incubated with TNF-α for the indicated time intervals. The
levels of phospho-p44/p42 MAPK were determined by Western blot. (D) HCFs were transfected with either scrambled or p42 siRNA, and then incubated with
TNF-α for 16 h. The levels of p42 and VCAM-1 protein were determined by Western blot. (E) HCFs were pretreated without or with TNFR nAb (10 μg/ml), Gö6976
(10 μM), edaravone (10 μM), or DPI (10 μM) for 1 h, and then incubated with TNF-α for the indicated time intervals. The levels of phospho-p44/p42 MAPK were
determined by Western blot. Data are expressed as mean ± SEM of three independent experiments (n = 3, Quantitative data of Figures 4C–E were presented in
Supplementary Table S1). ∗P < 0.05; #P < 0.01, as compared with the cells exposed to TNF-α alone.
(10 μM) (Figure 5E). These results suggested that TNF-
α activates TNFR/PKCα/Nox/ROS linking to p38 MAPK
phosphorylation and leading to VCAM-1 expression in
HCFs.
Involvement of JNK1/2 in TNF-α-Induced
VCAM-1 Expression
To determine the role of JNK1/2 signaling in VCAM-1
expression, pretreatment with JNK1/2 inhibitor (SP600125)
concentration-dependently attenuated TNF-α-induced VCAM-
1 expression (Figure 6A). TNF-α-induced VCAM-1 mRNA
expression and transcription activity was also attenuated by
pretreatment with SP600125 (10 μM) (Figure 6B). We further
determined whether TNF-α-stimulated JNK1/2 activation is
required for these responses, the activation of JNK1/2 was
determined by Western blot using an anti-phospho-JNK1/2
antibody. As shown in Figure 6C, TNF-α time-dependently
stimulated JNK1/2 phosphorylation with a maximal response
within 15 min, which was attenuated by pretreatment with
SP600125 (10 μM). To ensure the role of JNK1/2 in VCAM-
1 expression, as shown in Figure 6D, transfection with JNK1
siRNA knocked down JNK1 protein and also attenuated TNF-
α-induced VCAM-1 expression. Moreover, TNF-α-stimulated
JNK1/2 phosphorylation was also attenuated by pretreatment
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FIGURE 5 | Involvement of p38 MAPK in TNF-α-induced VCAM-1 expression in HCFs. (A) HCFs were pretreated with SB202190 (0.1, 1, or 10 μM) for 1 h,
and then incubated with TNF-α for 16 h. The protein levels of VCAM-1 were determined by Western blot. (B) Cells were pretreated with SB202190 (10 μM) for 1 h,
and then incubated with TNF-α for 4 h. The mRNA expression (white bar) and promoter activity (gray bar) of VCAM-1 were determined by real-time PCR or promoter
report assay, respectively. (C) Cells were pretreated with SB202190 (10 μM) for 1 h, and then incubated with TNF-α for the indicated time intervals. The levels of
phospho-p38 MAPK were determined by Western blot. (D) Cells were transfected with either scrambled or p38 MAPK siRNA, and then incubated with TNF-α for
16 h. The levels of p38 MAPK and VCAM-1 protein were determined by Western blot. (E) Cells were pretreated without or with TNFR nAb (10 μg/ml), Gö6976
(10 μM), edaravone (10 μM), or DPI (10 μM) for 1 h, and then incubated with TNF-α for the indicated time intervals. The levels of phospho-p38 MAPK were
determined by Western blot. Data are expressed as mean ± SEM of three independent experiments (n = 3, Quantitative data of Figures 5C–E were presented in
Supplementary Table S1). #P < 0.01, as compared with the cells exposed to TNF-α alone.
with TNFR nAb (10 μg/ml), Gö6976 (10 μM), Edaravone
(10 μM), or DPI (10 μM) (Figure 6E). These results suggested
that TNF-α-induced VCAM-1 expression is mediated through
TNFR-dependent PKCα/Nox/ROS pathway linking to JNK1/2
phosphorylation in HCFs.
AP-1 Involved in TNF-α-Induced VCAM-1
Expression
AP-1, heterodimer of c-Fos and c-Jun, is a well-known
transcription factor to participate in the expression of
inﬂammatory genes in various cell types (Hsieh and Yang,
2013). To determine whether AP-1 is involved in VCAM-1
expression, the AP-1 inhibitor, TSIIA, was used to block
the TNF-α-induced VCAM-1 expression. We found that
pretreatment with TSIIA obviously inhibited the TNF-α-induced
VCAM-1 expression in a concentration-dependent manner
(Figure 7A). Consistently, both of the TNF-α-induced VCAM-1
mRNA expression and promoter activity were also attenuated
with pretreatment of TSIIA (1 μM) (Figure 7B). We further
determine whether TNF-α stimulated AP-1 activation required
for VCAM-1 expression, the activated AP-1 was detected by
Western blot using an anti-phospho-c-Jun antibody. As shown
in Figure 7C, we found that TNF-α obviously stimulated c-Jun
phosphorylation with a maximal response within 15 min, which
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FIGURE 6 | Involvement of JNK1/2 in TNF-α-induced VCAM-1 expression in HCFs. (A) HCFs were pretreated with SP600125 (0.1, 1, or 10 μM) for 1 h, and
then incubated with TNF-α for 16 h. The protein levels of VCAM-1 were determined by Western blot. (B) HCFs were pretreated with SP600125 (10 μM) for 1 h, and
then incubated with TNF-α for 4 h. The mRNA expression (white bar) and promoter activity (gray bar) of VCAM-1 were determined by real-time PCR or promoter
report assay, respectively. (C) HCFs were pretreated with SP600125 (10 μM) for 1 h, and then incubated with TNF-α for the indicated time intervals. The levels of
phospho-JNK1/2 were determined by Western blot. (D) HCFs were transfected with either scrambled or JNK1 siRNA, and then incubated with TNF-α for 16 h. The
levels of JNK1 and VCAM-1 protein were determined by Western blot. (E) HCFs were pretreated without or with TNFR nAb (10 μg/ml), Gö6976 (10 μM), edaravone
(10 μM), or DPI (10 μM) for 1 h, and then incubated with TNF-α for the indicated time intervals. The levels of phospho-JNK1/2 were determined by Western blot.
Data are expressed as mean ± SEM of three independent experiments (n = 3, Quantitative data of Figures 6C–E were presented in Supplementary Table S2).
#P < 0.01, as compared with the cells exposed to TNF-α alone.
was also inhibited by pretreatment with TSIIA (1 μM). To
further ensure c-Jun/AP-1 involved in VCAM-1 expression,
c-Jun siRNA transfection was used to knock down c-Jun protein
expression. We found that knockdown of c-Jun protein also
attenuated TNF-α-induced VCAM-1 expression (Figure 7D).
Moreover, we also diﬀerentiated the signaling components
involved in TNF-α-stimulated the phosphorylation of c-Jun/AP-
1. The results of Western blot indicated that pretreatment with
TNFR nAb, Edaravone or DPI attenuated TNF-α-stimulated
c-Jun phosphorylation. Next, to investigate whether activation
of MAPKs led to c-Jun phosphorylation, we found that
pretreatment with Gö6976 (10 μM), U0126 (1 μM), or SP600125
(3 μM) and p38 siRNA transfection also inhibited TNF-
α-stimulated c-Jun phosphorylation (Figure 7E). Furthermore,
TNF-α time-dependently enhanced AP-1 transcription activity
with a maximal response within 2 h (Figure 7F, left), which
was also attenuated by pretreatment with TNFR nAb or
pharmacological inhibitors including Gö6976, DPI, Edaravone,
U0126, SB202190, SP600125, or TSIIA (Figure 7F, middle and
right). These results suggested that TNF-α-stimulated c-Jun/AP-
1 activation via TNFR-mediated PKCα/Nox/ROS/MAPKs is
required for up-regulation of VCAM-1 in HCFs.
TNF-α Promotes Monocytes Adhesion
Through an AP-1-Dependent
Up-Regulation of VCAM-1
Ultimately, we investigated the functional activity of up-regulated
VCAM-1 by TNF-α in HCFs. Previous reports indicate that
THP-1 monocytes can be used as a model system to mimetic
the adhesion of monocytes to upregulated adhesion molecules
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FIGURE 7 | Activation of c-Jun/AP-1 is required for TNF-α-mediated VCAM-1 expression. (A) HCFs were pretreated with TSIIA (0.01, 0.1, or 1 μM) for 1 h,
and then incubated with TNF-α for 16 h. The protein levels of VCAM-1 were determined by Western blot. (B) HCFs were pretreated with TSIIA (1 μM) for 1 h, and
then incubated with TNF-α for 4 h. The mRNA expression (white bar) and promoter activity (gray bar) of VCAM-1 were determined by real-time PCR or promoter
report assay, respectively. (C) HCFs were pretreated with TSIIA (1 μM) for 1 h, and then incubated with TNF-α for the indicated time intervals. The levels of
phospho-c-Jun were determined by Western blot. (D) HCFs were transfected with either scrambled or c-Jun siRNA, and then incubated with TNF-α for 16 h. The
levels of c-Jun and VCAM-1 protein were determined by Western blot. (E) HCFs were pretreated without or with TNFR nAb (10 μg/ml), Gö6976 (10 μM), edaravone
(10 μM), DPI (10 μM), U0126 (1 μM), SP600125 (3 μM) for 1 h, or p38 siRNA transfection, and then incubated with TNF-α for the indicated time intervals. The levels
of phospho-c-Jun were determined by Western blot. (F) HCFs were transiently cotransfected with pAP1-Luc and pCMV-Gal for 24 h, and then incubated with
TNF-α for the indicated time intervals (F, left). The transfected cells were pretreated with TNFR nAb, Gö6976, DPI, edaravone (Eda) (F, middle), apocynin (APO),
SB202190 (SB), SP600125 (SP), or TSIIA (F, right) for 1 h and then incubated with TNF-α for 2 h. The AP-1 transcription activity in the cell was determined as
described in Section “Materials and Methods”. Data are expressed as mean ± SEM of three independent experiments (n = 3, Quantitative data of Figures 7C–E
were presented in Supplementary Table S2). ∗P < 0.05; #P < 0.01, as compared with the cells exposed to TNF-α alone.
on cell surface of resident cells induced by various stimuli
(Goda et al., 2000; Wu et al., 2010; Liu et al., 2013). In this
report, THP-1 adhesion assay was performed to evaluate the
functional activity of VCAM-1 expression in TNF-α-challenged
HCFs. Our results indicated that treatment of HCFs with
TNF-α signiﬁcantly increased the adhesion of THP-1 monocyte
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FIGURE 8 | Up-regulated VCAM-1 by TNF-α contributes to promotion of monocyte adhering to these HCFs. (A) For cell adhesion activity, cells were
pretreated with VCAM-1 nAb, TNFR nAb, Gö6976 (Gö), DPI, edaravone (Eda) (Figure 7A, upper), U0126 (U0), SB202190 (SB), SP600125 (SP), or TSIIA
(Figure 7A, lower) for 1 h and following by TNF-α (15 μg/ml) for 16 h prior to addition of THP-1 monocytes. The adhesion activity was determined by cell adhesion
assay as described in Section “Materials and Methods”. Data are expressed as mean ± SEM of at least five individual experiments (n = 5). #P < 0.01 as compared
with TNF-α alone. (B) Schematic signaling pathways are involved in TNF-α-induced VCAM-1 expression in HCFs. TNF-α-induced VCAM-1 expression is triggered by
TNF-α/TNFR-mediated signaling pathways. TNF-α-mediated responses are dependent on PKC-α-activated Nox/ROS/MAPKs cascades linking to c-Jun/AP-1
transcription activity. Up-regulation of VCAM-1 contributes to enhancement of monocyte adhering to these HCFs challenged with TNF-α. Understanding the
mechanisms of VCAM-1 up-regulated by TNF-α on HCFs may provide rationally therapeutic interventions for heart injury or inflammatory diseases.
to HCFs (∼5-folds) which was attenuated by pretreatment
with VCAM-1 nAb or TNFR nAb (Figure 8A, upper). As
mentioned above, pretreatment with DPI, Gö6976, Edaravone,
U0126, SB202190, SP600125, and TSIIA attenuated the TNF-
α-induced VCAM-1 expression, consistently, the number of
monocytes attached to TNF-α-challenged HCFs was also reduced
by these pharmacological inhibitors (Figure 8A). These results
suggested that up-regulation of VCAM-1 via TNFR-mediated
PKCα/Nox/ROS/MAPKs/AP-1 pathway plays a critical role to
promote monocytes adhesion to TNF-α-challenged HCFs.
DISCUSSION
Up-regulation of adhesion molecules on the surface of the
heart cells plays a key role in the recruitment and inﬁltration
of leukocytes at sites of inﬂammation in heart inﬂammatory
disorders (Bedard and Krause, 2007; Cheng et al., 2009; Cook-
Mills et al., 2011). TNF-α has been conﬁrmed to induce
VCAM-1 expression in various cell types such as synovial
ﬁbroblasts (TorreAmione et al., 1996), but the intracellular
signaling mechanisms remain unclear in HCFs. Moreover, TNF-
α has also been shown to activate various signaling molecules
including protein kinases (e.g., PKCs), ROS, and MAPKs in
several cell types (TorreAmione et al., 1996; Lin et al., 2012;
Chi et al., 2014). Herein, we investigate detail mechanisms
underlying TNF-α-induced VCAM-1 expression in HCFs and its
eﬀects on monocytes adhesion. We found that in HCFs, TNF-α
stimulates PKCα-dependent Nox/ROS production via TNFR1, in
turn initiates the activation of MAPK pathway and to accelerate
AP-1 phosphorylation. The AP-1 activity leads to enhancing
VCAM-1 promoter activity and then up-regulating VCAM-1
protein in these cells. In addition, the upregulation of VCAM-
1 was obviously correlated with monocytes adhesion to HCFs
challenged with TNF-α.
Excessive production of ROS has been shown to play
a causative role in numerous pathologies of heart diseases
(Yokoyama et al., 1997). ROS also exert as an internal
messenger to maintain normal physiological functions or the
side products of inﬂammatory responses in a concentration-
dependent manner (Lin et al., 2009). When exposed to oxidative
stress, excessive production of ROS may trigger deleterious
eﬀects within the heart. It has been shown that activated renal
mesangial cells produce large amounts of ROS which can lead
to impairing cellular functions and enhancing inﬂammatory
reactions (Lee et al., 2012). These immune cells are stimulated
when encountering inhaled microorganisms or other mediators
leading to the activation of Nox and the production of
ROS. It has been reported that Nox activation is involved in
the regulation of VCAM-1 expression and intracellular ROS
generation induced by various stimuli such as LPS and ammonia
(Reinehr et al., 2007; Lee et al., 2012). Therefore, we explored
that the roles of Nox-dependent ROS generation in HCFs is
associated with VCAM-1 expression in response to TNF-α.
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First, a potent and novel scavenger of free radicals, Edaravone
(Saito et al., 2012), was used to scavenge ROS including
hydroxyl radicals. Edaravone has been shown to protect against
mitochondrial injury in myocardial ischemia/reperfusion and
inhibits inﬂammatory responses (Kono et al., 2003; Rajesh
et al., 2003). In the present study, edaravone signiﬁcantly
inhibited the TNF-α-induced ROS generation and VCAM-1
protein, mRNA, and promoter activity, suggesting that ROS
signal is critical to TNF-α-induced VCAM-1 expression. Next,
DPI, a Nox inhibitor, was used to conﬁrm whether Nox-
derived ROS generation is involved in the response. Our
results showed that pretreatment with DPI attenuated TNF-
α-induced ROS generation and VCAM-1 expression, suggesting
that Nox plays an important role in these responses. We
further demonstrated that two Nox isoforms, including Nox2
and Nox4, contribute to TNF-α-induced VCAM-1 expression
by transfection with siRNA of Nox2 or Nox4. These data
are consistent with previous reports showing that Nox-
derived ROS generation is involved in VCAM-1 induction
by IL-1β in HTSMCs (Luo et al., 2009) or human renal
mesangial cells (Lee et al., 2012). In addition, we also
demonstrated that PKC(α) is an upstream molecule of Nox-
derived ROS generation by using the inhibitor or siRNA
of PKCα, consistent with the study indicating that PKCα
is involved in VCAM-1 expression in HTSMCs (Lee et al.,
2008) and cPLA2 expression in RA synovial ﬁbroblasts (Chi
et al., 2014). These results suggested that PKCα contributes
to TNF-α-induced Nox/ROS-mediated VCAM-1 expression in
HCFs.
Abnormal MAPK regulation might lead to various
inﬂammation and injury in the heart diseases (Hsieh et al., 2012;
Palomer et al., 2013). Among the MAPK family, ERK1/2, p38
MAPK, and JNK1/2 play critical roles in signaling pathways that
regulate cell growth and inﬂammation. These MAPK signaling
components were associated with the eﬀects of pro-inﬂammatory
mediators such as TNF-α (Lee et al., 2006; Lin et al., 2012). In
the present study, we demonstrated that ERK1/2, p38 MAPK,
and JNK1/2 are essentially required for VCAM-1 induction
by TNF-α, since TNF-α-induced responses were attenuated by
their respective pharmacological inhibitors or transfection with
siRNA. The involvement of MAPKs in VCAM-1 induced by
TNF-α was further conﬁrmed to analyze the phosphorylation of
ERK1/2, p38 MAPK, and JNK1/2. These ﬁndings were consistent
with our previous reports that VCAM-1 expression was
mediated through activation of ERK1/2, p38 MAPK, and JNK1/2
in TNF-α treated HTSMCs (Lee et al., 2006) and activation of
p38 MAPK by LPS in human renal mesangial cells (Reinehr
et al., 2007). Moreover, TNF-α-stimulated phosphorylation of
ERK1/2, p38 MAPK, and JNK1/2 was signiﬁcantly attenuated
by pretreatments with TNFR nAb, PKCα inhibitors (Gö6976),
ROS scavenger (edaravone), or Nox inhibitor (DPI and APO),
suggesting that PKCα-dependent Nox/ROS signals are crucial
for TNF-α-bound-TNFR-mediated MAPKs phosphorylation
in HCFs. Our results were consistent with the previous reports
showing that ROS-dependent MAPKs activity is involved in the
regulation of cellular functions by diverse stimuli in several cell
types (Reinehr et al., 2007; Cheng et al., 2009). External stimuli
activate distinct groups of MAPKs by a ROS-dependent manner
which may exhibit the cell type-speciﬁcity.
The progression of oxidative stress during cellular or tissue
injuries not only causes damage to cellular macromolecules by
oxidation, but also alters functional activity of transcription
factors to modulate the pattern of gene expression. Here we focus
on the roles of transcription factor AP-1, the ROS-dependent AP-
1 activity which is well-known to modulate gene transcriptions
during oxidative stress associated with inﬂammatory diseases
(Sen and Packer, 1996). To investigate the role of AP-1 in these
TNF-α-mediated responses, our results further indicated that
TNF-α stimulates phosphorylation of c-Jun, an AP-1 subunit, via
PKCα-mediated Nox/ROS linking to MAPK pathway. Moreover,
c-Jun/AP-1 plays the terminal acceptor of signal transduction
in TNF-α-induced VCAM-1 expression. Thus, to knockdown
the AP-1 activity with c-Jun siRNA transfection also prevents
the TNF-α-driven VCAM-1 expression. Previous reports also
provide evidence indicating that the upstream region of VCAM-
1 promoter contains a variety of putative responsible elements
including AP-1 consensus sequence in several cell types (Vesely
et al., 2009; Lin et al., 2012). Thus, we also conﬁrmed that TNF-
α-induced VCAM-1 promoter activity was mediated through
a TNFR-dependent PKCα-dependent Nox/ROS/MAPK/AP-1
pathway. These results are consistent with the reports indicating
that LPS triggers the activity of PKCs initiated the subsequent
activation of the MAPK pathways and AP-1 phosphorylation to
induce VCAM-1 expression in HTSMCs (Lin et al., 2009) and
human renal mesangial cells (Reinehr et al., 2007).
The inﬁltration of immune cells is due to up-regulation of
adhesion molecules such as VCAM-1 (Bedard and Krause, 2007;
Cheng et al., 2009; Cook-Mills et al., 2011), which contributes to
chronic inﬂammatory diseases including cardiovascular diseases.
The level of VCAM-1 is low on unstimulated endothelial
cells, which can be up-regulated after challenge with cytokines.
In the present study, we demonstrated that TNF-α-enhanced
monocyte (THP-1) adhesion through up-regulation of VCAM-
1 on HCFs was attenuated by VCAM-1 nAb. Moreover, these
signaling components implicated in VCAM-1 induction by TNF-
α were also correlated with TNF-α-enhanced monocyte adhesion
conﬁrmed by using respective pharmacological inhibitors. These
results indicated that TNF-α-induced VCAM-1 expression via
PKCα-dependent activation of Nox/ROS/MAPKs linking to AP-
1 pathway, which results in monocytes adhered to the TNF-
α-challenged HCFs. These results are consistent with a report
indicating that TNF-α enhanced immune cells adhesion via up-
regulation of VCAM-1 in HTSMCs (Lee et al., 2006) and RASFs.
CONCLUSION
Based on the observations from literatures and our ﬁndings,
we proposed a VCAM-1 gene expression model as shown in
Figure 8B to depict the implicated components of signaling
mechanisms in the TNF-α-treated HCFs. These ﬁndings
imply that because TNF-α triggers the signal transductions
of PKCα-mediated activation of Nox/ROS, MAPKs, and AP-
1 to up-regulation of VCAM-1 in HCFs, the expression of
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adhesion molecules could enhance the attachment and linkage
of monocytes to HCFs. The results provide new insights
to understand the mechanisms by which TNF-α stimulated
VCAM-1 expression in HCFs associated with amplifying the
inﬂammatory responses, supporting the hypothesis that TNF-
α may play a key role in the exaggeration of cardiac
diseases.
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